PDCD1 and metastatic melanoma: showed that FMT in anti‐PD‐1‐refractory patients with metastatic melanoma leads to clinical responses, accompanied by favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the TME.[296] Similarly, Davar et al.